JAK inhibitors: New Delays by FDA
During the past couple of weeks, three large companies, AbbVie, Lilly, and Pfizer have recieved requests by the FDA that essentially delay the approval of their atopical dermatitis drugs that function as JAK inhibitors (1). Pfizer has been developing abrocitinib, an oral drug that is a selective JAK inhibitor and is designed for treatment of …